UCH-L4 Inhibitors

Chemical inhibitors of ubiquitin C-terminal hydrolase L4 (UCH-L4) employ various mechanisms to impede the protein's function. LDN-57444, for instance, selectively targets UCH-L4 by binding to its active site, which is necessary for the hydrolysis of the carboxyl terminal ester and amide bonds of ubiquitin. This binding action directly inhibits the protein's deubiquitinating activity. Similarly, Vialinin A also inhibits UCH-L4 but does so by irreversibly attaching to its active site, thus blocking the deubiquitination process essential for protein degradation. IU1, a specific inhibitor of UCH-L4, binds to the enzyme's active site as well, preventing the cleavage of ubiquitin from polyubiquitinated proteins. This action directly obstructs the enzyme's normal function.

Other inhibitors, such as BAY 11-7082, HBX 41,108, and WP1130, inhibit UCH-L4 by modifying the active site cysteine residue, which is indispensable for its catalytic activity. BAY 11-7082 is known to react with the cysteine residue, while HBX 41,108 acts by binding to this crucial site, thereby hindering the protein's function. WP1130 distinguishes itself by selectively inhibiting UCH-L4 among other deubiquitinases, modifying the cysteine residue at the active site, which is essential for the enzyme's activity. Compounds like RA-9, P22077, and PR-619 also play a role in inhibiting UCH-L4. RA-9 prevents the enzyme from accessing its ubiquitin substrates, P22077 binds directly to the active site to inhibit activity, and PR-619 covalently modifies the active site, leading to a broad-spectrum inhibition of deubiquitination. NSC632839 and Spautin-1, although through differing modes of action-one by interacting with the active site and the other by promoting the degradation of deubiquitinating enzymes-each inhibit the function of UCH-L4. Lastly, EOAI3402143 inhibits the hydrolysis activity of UCH-L4, essential for the protein's role in regulating protein turnover.